A further reduction in MedDRA subscription fees for 2008

23 September 2007

The International Conference on Harmonization's Medical Dictionary for Regulatory Activities (MedDRA) management board has approved the proposed annual subscription rates for 2008. It says that, with a rapidly growing subscriber base, the actual cost of maintaining MedDRA continues to be shared across a larger number of subscribers. Consequently, for the third consecutive year, there will be a significant reduction for lower revenue subscribers, as well as no increases to other subscription levels.

In addition, access to MedDRA is now free for academic organizations, hospitals, health care providers and other users involved in non-commercial activities. Free MedDRA training for all new Basic, Core 0, and Core 1 subscribers is also being offered.

For 2008, for Core 1 subscribers ($1.0-$10.0 million in annual revenue) subscriptions are reduced 28% to $850 and Core 2 subscribers ($10.0-$500.0 million revenue a year) these are cut 5% to $5,850. The complete MedDRA subscription rates for 2008, which illustrates the significant decrease across all subscription levels since 2005, can be viewed on the ICH's web site at: www.ich.org.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight